JPRN-UMIN000001381已完成未知
A Phase 2/3 Study of SYR-322 as an Add-on to an Alpha-Glucosidase Inhibitor - A Phase 2/3 Study of SYR-322 as an Add-on to an Alpha-Glucosidase Inhibitor
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The subject has taken any antidiabetic medications except Alpha-glucosidase inhibitors within the last 4 weeks prior to the initiation of screening period(week -8) and during screening period.
研究者
相似试验
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a SulfonylureaType 2 diabetes mellitus.JPRN-jRCT2080220603Takeda Pharmaceutical Company Limited240
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a SulfonylureaType 2 diabetes mellitusJPRN-UMIN000001393Takeda Pharmaceutical Company Limited240
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a MetformiType 2 diabetes mellitusJPRN-UMIN000001394Takeda Pharmaceutical Company Limited240
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a MetformiType 2 diabetes mellitusJPRN-jRCT2080220606Takeda Pharmaceutical Company Limited240
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a ThiazolidineJPRN-jRCT2080220568Takeda Pharmaceutical Company Limited240